Innovative therapeutic approach: Sequential treatment with plasma exchange and eculizumab in a pregnant woman affected by atypical hemolytic-uremic syndrome

Transfusion and Apheresis Science

Volumn 51, Issue 2, 2014, Pages 134-136

  Mussoni, Maria Pia ^a   Veneziano, F A ^a   Boetti, L ^a   Tassi, C ^a   Calisesi, C ^a   Nucci, S ^a   Rigotti, A ^a   Panzini, I ^a   Ardissino, G ^b  

^a UO Immunohematology and Transfusion Medicine Rimini AUSL Romagna   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Atypical HUS; Eculizumab; Transfusion practices

Indexed keywords

AMOXICILLIN; COMPLEMENT FACTOR H; ECULIZUMAB; FRESH FROZEN PLASMA; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CASE REPORT; FAMILY HISTORY; FEMALE; GENE MUTATION; GESTATIONAL AGE; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAINTENANCE THERAPY; PLASMAPHERESIS; PREGNANT WOMAN; PROTEINURIA; RELAPSE; REMISSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; ATYPICAL HEMOLYTIC UREMIC SYNDROME; GENETIC DISEASES, INBORN; GENETICS; HOMOZYGOTE; MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT FACTOR H; FEMALE; GENETIC DISEASES, INBORN; HOMOZYGOTE; HUMANS; MUTATION; PLASMA EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC;

EID: 84922724222     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2014.08.027     Document Type: Article

References (9)

1. Mele C., Noris M. La sindrome emolitico uremica. G Ital Nefrol 2007, 24(1):23-33.
2. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:1676-1687.
3. Caprioli J., Noris M., Brioshi S., Pianetti G., Castelletti F., Bettinaglio P., et al. The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and out come. Blood 2006, 108:1267-1279.
4. Noris M., Caprioli J., Bresin E., Mossali C., Pianetti G., Gamba S., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010, 5:1844-1859.
5. Legendre C.M. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 368:2169-2181.
6. Kelly R. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol 2010, 149:446-450.
7. Ardissino G., Ossola M.W., Baffero G.M., Rigotti A., Cugno M. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol 2013, 122:487-489.
8. Fakhouri F., Roumenina L., Provot F., Sallée M., Caillard S., Couzi L., et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010, 21:859-867.
9. Koziolek M.J. Chronic course of a hemolytic uremic syndrome caused by a deficiency of factor H-related proteins (CFHR1 and CFHR3). Kidney Int 2008, 74:384-388.